Background: Managing disseminated nontuberculous mycobacterial (NTM) infection in patients with neutralizing anti-interferon-γ autoantibodies (AIGAs) poses substantial challenges due to the lack of established treatment guidance and predictive tools for clinical outcomes. In this study, we investigated the utility of F-fluorodeoxyglucose (2-[F]FDG) positron emission tomography (PET) in guiding treatment decisions, with a focus on its ability to predict rehospitalization outcomes.
Methods: We conducted a post hoc analysis of the first available 2-[F]FDG PET scans of patients with AIGAs and disseminated NTM infection from a prospective observational multicenter cohort. Cox proportional hazards regression was used to determine predictors for disease-related rehospitalization within 1 year of the examination.
Results: Of the patients with AIGAs evaluated, 41.9% required rehospitalization within 1 year following the initial 2-[F]FDG PET evaluation. Slowly growing mycobacteria were isolated in 64.5% of patients. Multivariable analysis identified splenic involvement (adjusted hazard ratio, 7.97; 95% CI, 2.34-27.16; < .001) as a significant predictor of disease-related rehospitalization within 1 year following the examination. Moreover, mediastinal node involvement (adjusted odds ratio, 14.77; 95% CI, 1.01-216.76; = .049) and axial skeleton involvement (adjusted odds ratio, 14.93; 95% CI, 1.11-201.43; = .042) were significantly associated with the isolation of slowly growing mycobacteria.
Conclusions: 2-[F]FDG PET appears useful in initial evaluation of disease extent and microbiology in patients with AIGAs and disseminated NTM infection. Identifying splenic involvement through this modality may help recognize patients at increased risk of disease-related rehospitalization within 1 year. These findings suggest that 2-[F]FDG PET could inform management decisions in this challenging population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656338 | PMC |
| http://dx.doi.org/10.1093/ofid/ofae708 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of hypometabolism in AD‐related regions in real‐world FDG‐PET of the brain.
Alzheimers Dement
December 2024
Vanderbilt Memory & Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN, USA
Background: Standard of care for many cancer workups includes whole‐body FDG PET/CT before, during, and after therapy. At Vanderbilt, these scans include the brain for every patient (>20,000 patients). Brain FDG PET is a validated assessment of neuronal health.
View Article and Find Full Text PDFPrevalence of hypometabolism in AD‐related regions in real‐world FDG‐PET of the brain.
Alzheimers Dement
December 2024
Vanderbilt Memory & Alzheimer’s Center, Vanderbilt University Medical Center, Nashville, TN, USA
Background: Standard of care for many cancer workups includes whole‐body FDG PET/CT before, during, and after therapy. At Vanderbilt, these scans include the brain for every patient (>20,000 patients). Brain FDG PET is a validated assessment of neuronal health.
View Article and Find Full Text PDFPET imaging of sodium-glucose cotransporters (SGLTs): Unveiling metabolic dynamics in diabetes and oncology.
Mol Metab
December 2024
Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany; Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. Electronic address:
Background: Sodium-glucose cotransporters (SGLTs) play a crucial role in glucose regulation and are essential therapeutic targets for diabetes management. Recent advancements have leveraged SGLT-targeted PET imaging to examine these transporters' roles in both health and disease.
Scope Of Review: This review highlights recent innovations in PET imaging targeting SGLTs, with a particular focus on SGLT-specific radiotracers, such as alpha-methyl-4-deoxy-4-F-fluoro-d-glucopyranoside (Me-4FDG).
Enhanced staging of extrahepatic hepatocellular carcinoma metastasis through dual-tracer PET/computed tomography: a systematic review and meta-analysis.
Nucl Med Commun
September 2024
Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
The aim of this study was to quantify the diagnostic value of dual-tracer PET/computed tomography (CT) with 11 C-acetate and fluorodeoxyglucose (FDG) in per-lesion and per-patient and its effect on clinical decision-making for choosing the most appropriate management. The study protocol is registered a priori at https://osf.io/rvm75/ .
View Article and Find Full Text PDFClinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.
Am J Cardiol
October 2023
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address:
Article Synopsis
- The study investigates the effects of TNF-α inhibitors, infliximab and adalimumab, on patients with cardiac sarcoidosis (CS), analyzing their disease progression through imaging and clinical outcomes.
- A total of 31 patients were observed, showing a significant reduction in their average prednisone dose and a notable decrease in the number of heart segments with elevated FDG uptake after treatment.
- Results suggest that TNF-α inhibitor therapy in CS patients leads to lower steroid use and minimal cardiac issues, although some patients experienced unplanned hospitalizations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!